, Volume 9, Issue 3, pp 137-141
Date: 19 Mar 2010

Efficacy of cetuximab combination with chemotherapy in non-small cell lung cancer first-line setting: the summary based on publications

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Objective

The combination of cetuximab with standard chemotherapy was not widely studied though it was recommended by NCCN 2009 to apply in non-small cell lung cancer (NSCLC) first-line setting. The aim of this study was to summary the efficacy and safety profiles of all the NSCLC patients available in openly published papers treated with above mentioned regimens.

Methods

The PubMed database was used to search all the papers on NSCLC associated with cetuximab treatment, and only the clinical trails applied cetuximab combined with doublets cytotoxic chemotherapy in first-line setting till to 30 November 2009 were collected. And the medians and their 95% CI of objective response rate (ORR), progression free survival (PFS), overall survival (OS), and the common adverse events were calculated.

Results

(1) Eight papers including 1032 patients were collected, and all cases were at advanced stage. (2) The ratio of male and female patients was 1.6, 50.1% patients were adenocarcinoma and 28.2% patients were squamous cell carcinoma (SCC), 90.0% patients were PS = 0–1, and 78.2% patients were white ethnic. (3) The disease control rate (DCR), ORR, PFS, and OS were 65.2% (95% CI: 60.7%–69.7%), 33.2% (95% CI: 30.3%–36.1%), 5.0 months (95% CI: 4.7–5.3) and 10.9 months (95% CI: 9.6–12.2), respectively.

Conclusion

This is the first study to summarize the efficacy and safety profiles of cetuximab combined with chemotherapy in NSCLC first-line setting based on all available patients. The addition of cetuximab caused promising prognosis and acceptable side effects excepting higher incidence of neutropenia, and febrile neutropenia.

Supported by the grant of Major Science and Technology Project of “National Significant New drug Creation” (No. 2008ZX09312-002).